|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-18
|
|
pubmed:abstractText |
The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AparicioAnaA,
pubmed-author:AsheRobynne GRG,
pubmed-author:CornPaulP,
pubmed-author:JohnsonMarcella MMM,
pubmed-author:JonaschEricE,
pubmed-author:NgChaanC,
pubmed-author:PagliaroLance CLC,
pubmed-author:TamboliPherozeP,
pubmed-author:TannirNizar MNM,
pubmed-author:WarnekeCarla LCL,
pubmed-author:WrightJohn JJJ
|
|
pubmed:copyrightInfo |
Copyright 2010 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
57-65
|
|
pubmed:meshHeading |
pubmed-meshheading:19862815-Aged,
pubmed-meshheading:19862815-Aged, 80 and over,
pubmed-meshheading:19862815-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19862815-Benzenesulfonates,
pubmed-meshheading:19862815-Carcinoma, Renal Cell,
pubmed-meshheading:19862815-Disease-Free Survival,
pubmed-meshheading:19862815-Female,
pubmed-meshheading:19862815-Humans,
pubmed-meshheading:19862815-Interferon-alpha,
pubmed-meshheading:19862815-Kidney Neoplasms,
pubmed-meshheading:19862815-Male,
pubmed-meshheading:19862815-Middle Aged,
pubmed-meshheading:19862815-Pyridines,
pubmed-meshheading:19862815-Tumor Markers, Biological
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
|
|
pubmed:affiliation |
Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. ejonasch@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
